Cerus Corp. (NASDAQ:CERS) shares saw an uptick in trading volume on Friday . 1,242,206 shares were traded during mid-day trading, an increase of 5% from the previous session’s volume of 1,179,011 shares.The stock last traded at $6.40 and had previously closed at $6.36.

A number of analysts recently commented on CERS shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 target price on shares of Cerus Corp. in a research report on Thursday. Robert W. Baird reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Cerus Corp. in a research report on Wednesday, June 22nd. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Cerus Corp. in a research report on Monday, June 20th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Cerus Corp. in a research report on Monday, May 23rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $8.90.

The company’s market capitalization is $656.03 million. The company has a 50 day moving average price of $5.92 and a 200 day moving average price of $5.80.

Cerus Corp. (NASDAQ:CERS) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.01. The firm earned $7.60 million during the quarter, compared to analysts’ expectations of $8.29 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The company’s revenue was down 1.3% on a year-over-year basis. On average, equities research analysts predict that Cerus Corp. will post ($0.65) earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Rail Splitter Capital Management LLC raised its stake in Cerus Corp. by 19.0% in the fourth quarter. Rail Splitter Capital Management LLC now owns 832,722 shares of the company’s stock worth $5,263,000 after buying an additional 132,970 shares in the last quarter. Stephens Inc. AR raised its stake in Cerus Corp. by 11.3% in the fourth quarter. Stephens Inc. AR now owns 1,112,665 shares of the company’s stock worth $7,032,000 after buying an additional 113,238 shares in the last quarter. Wells Fargo & Company MN raised its stake in Cerus Corp. by 25.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,901,666 shares of the company’s stock worth $30,979,000 after buying an additional 1,007,430 shares in the last quarter. EAM Investors LLC purchased a new stake in Cerus Corp. during the fourth quarter worth $1,139,000. Finally, California State Teachers Retirement System raised its stake in Cerus Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 176,709 shares of the company’s stock worth $1,117,000 after buying an additional 3,126 shares in the last quarter.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.